[go: up one dir, main page]

WO1996041813A3 - Polymeres fonctionnalises destines a une ligation dirigee - Google Patents

Polymeres fonctionnalises destines a une ligation dirigee Download PDF

Info

Publication number
WO1996041813A3
WO1996041813A3 PCT/IB1995/001175 IB9501175W WO9641813A3 WO 1996041813 A3 WO1996041813 A3 WO 1996041813A3 IB 9501175 W IB9501175 W IB 9501175W WO 9641813 A3 WO9641813 A3 WO 9641813A3
Authority
WO
WIPO (PCT)
Prior art keywords
functionalized
site
family
topology
aldehyde
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB1995/001175
Other languages
English (en)
Other versions
WO1996041813A9 (fr
WO1996041813A2 (fr
Inventor
Robin E Offord
Hubert F Gaertner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to EP95944855A priority Critical patent/EP0788375A2/fr
Priority to JP8535165A priority patent/JPH10509208A/ja
Priority to AU73272/96A priority patent/AU7327296A/en
Publication of WO1996041813A2 publication Critical patent/WO1996041813A2/fr
Anticipated expiration legal-status Critical
Publication of WO1996041813A3 publication Critical patent/WO1996041813A3/fr
Publication of WO1996041813A9 publication Critical patent/WO1996041813A9/fr
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Other Resins Obtained By Reactions Not Involving Carbon-To-Carbon Unsaturated Bonds (AREA)
  • Polyethers (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)

Abstract

On décrit des polymères organiques, par exemple un poly(éthylène glycol), fonctionnalisé à l'aide d'un groupe amino-oxy formant une oxime, ainsi que des procédés de préparation et d'utilisation de ceux-ci dans une ligation chimiosélective, dirigée, avec une macromolécule cible, ou une surface, fonctionnalisée par un aldéhyde (ou une cétone), dans des conditions de ligation modérées. On décrit également des structures polymères de recombinaison, lesquelles contiennent des multi-polymères, sont fonctionnalisés par amino-oxy ou par un aldéhyde (ou une cétone), et permettent une ligation chimiosélective dirigée, dans des conditions modérées, de la structure de recombinaison (et, ainsi, de tous les polymères de celle-ci) avec un seul site d'une macromolécule cible, via une liaison oxime. On décrit encore des familles de structures de polymères de recombinaison fonctionnalisés, dans lesquelles chaque structure diffère de celles de la même famille quant à sa topologie mais non quant à son poids moléculaire (moyen). Des procédés d'utilisation de ces polymères comprennent la modification systématique d'une macromolécule cible, afin de créer rapidement une famille de molécules cibles, de préférence des protéines biologiquement importantes, différant quant à leur topologie mais non quant à leur poids moléculaire, famille à partir de laquelle on peut identifier des macromolécules possédant les propriétés biologiques ou physiques souhaitées, telles qu'un meilleur comportement pharmacocinétique.
PCT/IB1995/001175 1994-11-09 1995-11-09 Polymeres fonctionnalises destines a une ligation dirigee Ceased WO1996041813A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP95944855A EP0788375A2 (fr) 1994-11-09 1995-11-09 Polymeres fonctionnalises destines a une ligation dirigee
JP8535165A JPH10509208A (ja) 1994-11-09 1995-11-09 部位特異的結合のための官能化されたポリマー
AU73272/96A AU7327296A (en) 1994-11-09 1996-11-09 Functionalized polymers for site-specific attachment

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US33685094A 1994-11-09 1994-11-09
US08/336,850 1994-11-09
US39469095A 1995-02-23 1995-02-23
US08/394,690 1995-02-23

Publications (3)

Publication Number Publication Date
WO1996041813A2 WO1996041813A2 (fr) 1996-12-27
WO1996041813A3 true WO1996041813A3 (fr) 1997-05-22
WO1996041813A9 WO1996041813A9 (fr) 1997-06-19

Family

ID=26990408

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB1995/001175 Ceased WO1996041813A2 (fr) 1994-11-09 1995-11-09 Polymeres fonctionnalises destines a une ligation dirigee

Country Status (4)

Country Link
EP (1) EP0788375A2 (fr)
AU (1) AU7327296A (fr)
CA (1) CA2204726A1 (fr)
WO (1) WO1996041813A2 (fr)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6951939B2 (en) 2000-06-08 2005-10-04 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US7351855B2 (en) 1992-07-15 2008-04-01 La Jolla Pharmaceutical Company Chemically defined non-polymeric valency platform molecules and conjugates thereof
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US8058433B2 (en) 2000-03-30 2011-11-15 Abbott Laboratories Crystalline pharmaceutical
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9525955D0 (en) * 1995-12-19 1996-02-21 Therexsys Ltd Improved pharmaceutical compositions
US5830852A (en) * 1995-12-19 1998-11-03 Cobra Therapeutics, Ltd. Compositions for insulin-receptor mediated nucleic acid delivery
CN1161127C (zh) 1997-07-03 2004-08-11 奥奎斯特公司 交联的多糖药物载体
FI980489A7 (fi) * 1998-03-04 1999-09-05 Alexei Radievich Khomutov Syklodekstriinien uudet johdannaiset
US7691367B2 (en) 1999-12-24 2010-04-06 Kyowa Hakko Kirin Co., Ltd. Branched polyalkylene glycols
DE60139110D1 (de) 2000-01-10 2009-08-13 Maxygen Holdings Ltd G-csf konjugate
EP2319541A1 (fr) 2000-02-11 2011-05-11 Bayer HealthCare LLC Conjugués de type facteur VII ou VIIA
HK1056113A1 (zh) * 2000-06-30 2004-02-06 Smithkline Beecham Corporation 趋化因子共轭物
US7118737B2 (en) 2000-09-08 2006-10-10 Amylin Pharmaceuticals, Inc. Polymer-modified synthetic proteins
US20030191291A1 (en) * 2000-09-08 2003-10-09 Kochendoerfer Gerd G. Synthetic erythropoiesis stimulating proteins
AR030631A1 (es) * 2000-09-29 2003-08-27 Abbott Lab Polipeptidos antiangiogenicos y metodos para inhibir la angiogenesis
AU2002217863A1 (en) * 2000-12-01 2002-06-11 Conforma Therapeutic Corporation Homing peptide multimers, their preparation and uses
AU3323002A (en) 2000-12-20 2002-07-01 Hoffmann La Roche Erythropoietin conjugates
EP2080771A3 (fr) 2001-02-27 2010-01-06 Maxygen Aps Nouvelles molécules de type interféron beta
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
CN101301475B (zh) 2002-06-21 2012-12-19 诺和诺德医疗保健公司 Peg化因子vii糖型
AU2003292632A1 (en) * 2002-12-26 2004-07-22 Shionogi Co., Ltd. Method of purifying/concentrating sugar chain with sugar chain-trapping molecule and method of analyzing sugar chain structure
CN102139114A (zh) 2003-02-26 2011-08-03 尼克塔治疗公司 聚合物-因子viii部分缀合物
US20040249119A1 (en) * 2003-06-05 2004-12-09 Fox Martin Edward Novel mPEG propionaldehyde precursor
EP1653991A2 (fr) * 2003-08-08 2006-05-10 Fresenius Kabi Deutschland GmbH Conjugues de polymere et de proteine lies au moyen d'un groupe de liaison oxime
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
EP1673387B1 (fr) 2003-10-10 2010-09-15 Novo Nordisk A/S Derives de il-21
EP2633866A3 (fr) 2003-10-17 2013-12-18 Novo Nordisk A/S Thérapie combinée
EP2033662B1 (fr) 2004-01-21 2012-10-17 Novo Nordisk Health Care AG Conjugaison de peptides induite par la transglutaminase.
WO2005074650A2 (fr) 2004-02-02 2005-08-18 Ambrx, Inc. Polypeptides a faisceau a quatre helices (4hb) humains modifies, et leur utilisation
SI2363414T1 (sl) 2004-11-12 2022-09-30 Bayer Healthcare Llc Usmerjena modifikacija FVIII
NZ555206A (en) 2004-12-22 2010-09-30 Ambrx Inc Methods for expression and purification of recombinant human growth hormone
CA2594557C (fr) 2004-12-22 2016-04-26 Ambrx, Inc. Hormone de croissance humaine modifiee
WO2006071840A2 (fr) 2004-12-22 2006-07-06 Ambrx, Inc. Formulations d'hormone de croissance humaine comportant un acide amine code de maniere non naturelle
CA2590429C (fr) 2004-12-22 2014-10-07 Ambrx, Inc. Compositions de synthetase d'aminoacyl-arnt et utilisations correspondantes
US7638491B2 (en) 2004-12-22 2009-12-29 Ambrx, Inc. Therapies using non-natural amino acids and polypeptides
CN103030690A (zh) 2005-06-03 2013-04-10 Ambrx公司 经改良人类干扰素分子和其用途
WO2006134173A2 (fr) 2005-06-17 2006-12-21 Novo Nordisk Health Care Ag Reduction et derivation selectives de proteines conçues par le genie genetique comprenant au moins une cysteine non native
NZ565294A (en) 2005-08-18 2010-06-25 Ambrx Inc Compositions of tRNA and uses thereof
EP1954710B1 (fr) 2005-11-08 2011-03-02 Ambrx, Inc. Accelerateurs destines a la modification d acides amines non-naturels et de polypeptides formes d'acides amines non-naturels
CN101454461A (zh) 2005-11-16 2009-06-10 Ambrx公司 包括非天然氨基酸的方法和组合物
SG170116A1 (en) 2005-12-14 2011-04-29 Ambrx Inc Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
BRPI0712008A2 (pt) 2006-05-24 2012-01-10 Novo Nordisk Healthcare Ag derivados e análogos de fix prolongados
US9175061B2 (en) 2006-07-07 2015-11-03 Novo Nordisk Health Care Ag Protein conjugates and methods for their preparation
AU2007292893B2 (en) 2006-09-08 2012-03-01 Ambrx, Inc. Suppressor tRNA transcription in vertebrate cells
CA2663083A1 (fr) 2006-09-08 2008-03-13 Ambrx, Inc. Polypeptide plasmatique humain modifie ou squelettes de fc et leurs utilisations
CN101541955B (zh) 2006-09-08 2016-09-28 Ambrx公司 用于脊椎动物细胞的杂合抑制tRNA
CA2666426A1 (fr) 2006-10-26 2008-05-02 Novo Nordisk A/S Variantes il-21
US7902332B2 (en) 2006-11-30 2011-03-08 General Electric Company Fluorine-labeled compounds
AU2007333049B2 (en) 2006-12-15 2014-02-20 Takeda Pharmaceutical Company Limited Factor VIIa-(poly)sialic acid conjugate having prolonged in vivo half-life
DK2068909T3 (da) 2007-03-30 2012-08-06 Ambrx Inc Modificerede FGF-21-polypeptider og anvendelse heraf
MX2009011870A (es) 2007-05-02 2009-11-12 Ambrx Inc Polipeptidos de interferon beta modificados y usos de los mismos.
MX338336B (es) 2007-11-20 2016-04-07 Ambrx Inc Polipeptidos de insulina modificados y sus usos.
MX2010008632A (es) 2008-02-08 2010-08-30 Ambrx Inc Leptina-polipeptidos modificados y sus usos.
WO2009113578A1 (fr) * 2008-03-13 2009-09-17 味の素株式会社 Substance d'élimination de composé carbonyle
JP5680534B2 (ja) 2008-07-23 2015-03-04 イーライ リリー アンド カンパニー 修飾されているウシｇ−ｃｓｆポリペプチドおよびそれらの使用
MX357314B (es) 2008-09-26 2018-07-04 Ambrx Inc Microorganismos y vacunas dependientes de replicacion de aminoacidos no naturales.
CN102232085A (zh) 2008-09-26 2011-11-02 Ambrx公司 修饰的动物促红细胞生成素多肽和其用途
CA2755395C (fr) 2009-03-20 2015-02-24 Hanmi Holdings Co., Ltd. Procede de preparation d'un conjugue de polypeptide physiologiquement actif et specifique d'un site
US8067526B2 (en) 2009-03-27 2011-11-29 Nof Corporation Method for producing polyoxalkylene derivative
US8642737B2 (en) 2010-07-26 2014-02-04 Baxter International Inc. Nucleophilic catalysts for oxime linkage
US8809501B2 (en) 2009-07-27 2014-08-19 Baxter International Inc. Nucleophilic catalysts for oxime linkage
WO2011017055A2 (fr) * 2009-07-27 2011-02-10 Baxter International Inc. Conjugués de protéine de coagulation sanguine
NZ597600A (en) 2009-07-27 2014-05-30 Lipoxen Technologies Ltd Glycopolysialylation of non-blood coagulation proteins
RU2744370C2 (ru) 2009-07-27 2021-03-05 Баксалта Инкорпорейтед Конъюгаты белков свертывания крови
CN107056929A (zh) 2009-12-21 2017-08-18 Ambrx 公司 经过修饰的猪促生长素多肽和其用途
MX349301B (es) 2009-12-21 2017-07-21 Ambrx Inc Polipéptidos de somatotropina bovina modificados y sus usos.
EP2542569B1 (fr) 2010-03-05 2020-09-16 Omeros Corporation Molécules chimériques inhibitrices d'activation du complément
JP2013528374A (ja) 2010-05-10 2013-07-11 パーシード セラピューティクス リミテッド ライアビリティ カンパニー Ｖｌａ４のポリペプチド阻害剤
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
CN103201285A (zh) 2010-08-17 2013-07-10 阿姆布埃克斯股份有限公司 经修饰松弛素多肽及其用途
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
US8409526B2 (en) 2010-12-09 2013-04-02 General Electric Company Cellulose substrates, compositions and methods for storage and analysis of biological materials
JP6138052B2 (ja) 2010-12-22 2017-05-31 バクスアルタ ゲーエムベーハー 水溶性脂肪酸誘導体をタンパク質に抱合させるための材料および方法
HK1199889A1 (en) 2011-07-01 2015-07-24 Bayer Intellectual Property Gmbh Relaxin fusion polypeptides and uses thereof
EP2859017B1 (fr) 2012-06-08 2019-02-20 Sutro Biopharma, Inc. Anticorps comprenant des résidus d'acides aminés non endogènes spécifiques d'un site, leurs procédés de préparation et leurs procédés d'utilisation
EP2859013B1 (fr) * 2012-06-12 2016-08-31 Fina Biosolutions LLC Fonctionnalisation différentielle des polymères avec des réactifs amino oxy pour des dosages diagnostiques
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
EP3584255B1 (fr) 2012-08-31 2022-02-16 Sutro Biopharma, Inc. Acides aminés modifiés comprenant un groupe azido
WO2015006555A2 (fr) 2013-07-10 2015-01-15 Sutro Biopharma, Inc. Anticorps comprenant plusieurs résidus d'acides aminés non naturels site-spécifiques, des procédés permettant leur préparation et leurs méthodes d'utilisation
EP3055298B1 (fr) 2013-10-11 2020-04-29 Sutro Biopharma, Inc. Acides aminés modifiés comprenant des groupes fonctionnels de tétrazine, procédés de préparation et procédés d'utilisation associés
JP6721572B2 (ja) 2014-05-23 2020-07-15 ノバルティス アーゲー ジスルフィド含有タンパク質からコンジュゲートを作製するための方法
CA3052639A1 (fr) 2017-02-08 2018-08-16 Bristol-Myers Squibb Company Polypeptides de relaxine modifies comprenant un activateur pharmacocinetique et leurs utilisations
WO2020056066A1 (fr) 2018-09-11 2020-03-19 Ambrx, Inc. Conjugués polypeptidiques d'interleukine-2 et leurs utilisations
JP2022512746A (ja) 2018-10-19 2022-02-07 アンブルックス，インコーポレイテッド インターロイキン－１０ポリペプチド複合体、その二量体、およびそれらの使用
AU2020223031B2 (en) 2019-02-12 2024-08-29 Ambrx, Inc. Compositions containing, methods and uses of antibody-TLR agonist conjugates
JP2023517595A (ja) 2020-03-11 2023-04-26 アンブルックス，インコーポレイテッド インターロイキン－２ポリペプチド結合物およびその使用方法
WO2022040596A1 (fr) 2020-08-20 2022-02-24 Ambrx, Inc. Conjugués anticorps-agonistes de tlr, procédés et utilisations de ceux-ci
KR20240004342A (ko) 2021-04-03 2024-01-11 암브룩스, 인코포레이티드 항-her2 항체-약물 접합체 및 이의 용도

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539167A2 (fr) * 1991-10-21 1993-04-28 Ortho Pharmaceutical Corporation Imidates de PEG et leurs dérivés protéiniques
EP0605963A2 (fr) * 1992-12-09 1994-07-13 Ortho Pharmaceutical Corporation Réactifs pour la formation de liaisons de peg-hydrazone et peg-oxime et leurs dérives de protein
WO1994025071A1 (fr) * 1993-05-05 1994-11-10 Keith Rose Composes de polyoximes et leur preparation
WO1996011953A1 (fr) * 1994-10-12 1996-04-25 Amgen Inc. Compositions de proteines ayant subi une modification chimique a l'extremite n-terminale et procedes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0539167A2 (fr) * 1991-10-21 1993-04-28 Ortho Pharmaceutical Corporation Imidates de PEG et leurs dérivés protéiniques
EP0605963A2 (fr) * 1992-12-09 1994-07-13 Ortho Pharmaceutical Corporation Réactifs pour la formation de liaisons de peg-hydrazone et peg-oxime et leurs dérives de protein
WO1994025071A1 (fr) * 1993-05-05 1994-11-10 Keith Rose Composes de polyoximes et leur preparation
WO1996011953A1 (fr) * 1994-10-12 1996-04-25 Amgen Inc. Compositions de proteines ayant subi une modification chimique a l'extremite n-terminale et procedes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
VILASECA L ET AL: "PROTEIN CONJUGATES OF DEFINED STRUCTURE: SYNTHESIS AND USE OF A NEW CARRIER MOLECULE", BIOCONJUGATE CHEMISTRY, vol. 4, no. 6, 1 November 1993 (1993-11-01), pages 515 - 520, XP000417288 *

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7351855B2 (en) 1992-07-15 2008-04-01 La Jolla Pharmaceutical Company Chemically defined non-polymeric valency platform molecules and conjugates thereof
US8058433B2 (en) 2000-03-30 2011-11-15 Abbott Laboratories Crystalline pharmaceutical
US6951939B2 (en) 2000-06-08 2005-10-04 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US8916518B2 (en) 2002-03-06 2014-12-23 Fresenius Kabi Deutschland Gmbh Coupling proteins to a modified polysaccharide
US7538092B2 (en) 2002-10-08 2009-05-26 Fresenius Kabi Deutschland Gmbh Pharmaceutically active oligosaccharide conjugates
US8840879B2 (en) 2004-03-11 2014-09-23 Fresenius Kabi Deutschland Gmbh Conjugates of hydroxyalkyl starch and a protein
US7632924B2 (en) 2004-06-18 2009-12-15 Ambrx, Inc. Antigen-binding polypeptides and their uses
US7638299B2 (en) 2004-07-21 2009-12-29 Ambrx, Inc. Biosynthetic polypeptides utilizing non-naturally encoded amino acids
US8293708B2 (en) 2005-08-30 2012-10-23 Novo Nordisk Health Care A/G Liquid formulations N-terminal serine of pegylated growth hormone
US9434778B2 (en) 2014-10-24 2016-09-06 Bristol-Myers Squibb Company Modified FGF-21 polypeptides comprising an internal deletion and uses thereof

Also Published As

Publication number Publication date
EP0788375A2 (fr) 1997-08-13
CA2204726A1 (fr) 1996-12-27
EP0788375A3 (fr) 1997-09-17
WO1996041813A2 (fr) 1996-12-27
AU7327296A (en) 1997-01-09

Similar Documents

Publication Publication Date Title
WO1996041813A3 (fr) Polymeres fonctionnalises destines a une ligation dirigee
WO2001002017A3 (fr) Derives de l'erythropoietine
WO2001032146A3 (fr) Vesicules polymeres amphiphiles
WO2005061005A3 (fr) Echafaudages moleculaires ramifies destines a lier des residus polymeres a des groupes fonctionnels biologiquement actifs
AU6279900A (en) Polymer blends with improved impact resistance
DE60229955D1 (de) Zusammensetzungen, welche stäbchenförmige polymere und nanoröhrenförmige strukturen umfassen, sowie verfahren zur herstellung derselben
CA2315034A1 (fr) Materiau polymere contenant n, p, s, as ou se et composition de materiau de transfert de charge
EP1054031A3 (fr) Augmentation de la masse moléculaire et modification de polymères de condensation
EP1947145A3 (fr) Mélanges de polyesters biodégradables et produits fabriqués à partir de ceux-ci
ATE156158T1 (de) Makromoleküle auf basis von dendritischen polymeren und verfahren zur herstellung
WO1999003516A3 (fr) Reticulats polymeres semi-interpenetrants
NO954434D0 (no) Bioaktive og/eller målsökende dendrimer-konjugater
Hachaichi et al. Effect of alkali surface treatment and compatibilizer agent on tensile and morphological properties of date palm fibers‐based high density polyethylene biocomposites
DE60025475D1 (de) Herstellung von polymerteilchen
ATE455831T1 (de) Verbesserte polyolefinbasierende klebharze und verfahren zur herstellung von klebharzen
Kim et al. UV-induced graft copolymerization of monoacrylate-poly (ethylene glycol) onto poly (3-hydroxyoctanoate) to reduce protein adsorption and platelet adhesion
WO2001077197A3 (fr) Hydrogels et procedes de preparation associe
Ouchi et al. Mechanical property and biodegradability of solution‐cast films prepared from amphiphilic polylactide‐grafted dextran
WO1999054349A3 (fr) Molecules d'acides nucleiques dermatophagoides, proteines et leurs utilisations
CA2333379A1 (fr) Polymere contenant du lactide et materiau medical
AU2002215854A1 (en) Method for producing meltable polyesters
EP1236747A4 (fr) Caoutchouc effile aromatique-vinyle/diene-conjugue copolymere, procede de fabrication et composition de caoutchouc
BR9917391B1 (pt) processo para a polimerização de uma ou mais olefinas, e, processo para estreitar a distribuição do peso molecular de um polìmero, compreendendo uma ou mais olefinas.
DE60238816D1 (de) Prozess zur herstellung von isobutylenpolymeren mit hohem molekulargewicht
DE59903922D1 (de) Asa-formmassen zur herstellung matter formteile

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2204726

Country of ref document: CA

Ref country code: CA

Ref document number: 2204726

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: A3

Designated state(s): AU CA JP

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: 1995944855

Country of ref document: EP

COP Corrected version of pamphlet

Free format text: PAGES 1/7-7/7,DRAWINGS,REPLACED BY NEW PAGES BEARING THE SAME NUMBER;DUE TO LATE TRANSMITTAL BY THERECEIVING OFFICE

WWP Wipo information: published in national office

Ref document number: 1995944855

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995944855

Country of ref document: EP